Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1974 1
1976 1
1977 2
1979 2
1980 1
1981 3
1982 2
1983 3
1984 1
1985 3
1986 1
1987 1
1988 3
1989 2
1990 5
1991 3
1992 3
1993 6
1994 5
1995 7
1996 7
1997 6
1998 4
1999 5
2000 8
2001 8
2002 8
2003 6
2004 4
2005 8
2006 9
2007 5
2008 9
2009 11
2010 10
2011 8
2012 12
2013 9
2014 13
2015 14
2016 10
2017 8
2018 7
2019 10
2020 18
2021 14
2022 22
2023 15
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for alone baum
Search for Alona Baum instead (1 results)
Dexamethasone in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. RECOVERY Collaborative Group, et al. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. N Engl J Med. 2021. PMID: 32678530 Free PMC article. Clinical Trial.
METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual …
METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we r …
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
METHODS: We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-ac …
METHODS: We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Do …
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Wallentin L, et al. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717846 Free article. Clinical Trial.
Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular cause …
Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well a …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.
Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein 75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard …
Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation ( …
Magnetic Foreign Body Ingestions.
Alfonzo MJ, Baum CR. Alfonzo MJ, et al. Pediatr Emerg Care. 2016 Oct;32(10):698-702. doi: 10.1097/PEC.0000000000000927. Pediatr Emerg Care. 2016. PMID: 27749667 Review.
Magnets are inherently attractive to young children, but present a risk when ingested. If consumed alone, small, smooth magnetic foreign bodies are likely to pass without significant event; however, ingestion of multiple magnets may have catastrophic consequences, includin …
Magnets are inherently attractive to young children, but present a risk when ingested. If consumed alone, small, smooth magnetic fore …
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2022 Jul 30;400(10349):359-368. doi: 10.1016/S0140-6736(22)01109-6. Lancet. 2022. PMID: 35908569 Free PMC article.
Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). ...FINDINGS: Between Feb 2 and Dec …
Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual car …
Treatment of primary hyperoxaluria type 1.
Gupta A, Somers MJG, Baum MA. Gupta A, et al. Clin Kidney J. 2022 May 17;15(Suppl 1):i9-i13. doi: 10.1093/ckj/sfab232. eCollection 2022 May. Clin Kidney J. 2022. PMID: 35592620 Free PMC article. Review.
Once plasma oxalate levels exceed 30 mol/L, aggressive haemodialysis is indicated to prevent oxalosis, even if the glomerular filtration rate (GFR) remains better than for typical dialysis initiation. Peritoneal dialysis alone does not achieve the needed oxalate clearance. …
Once plasma oxalate levels exceed 30 mol/L, aggressive haemodialysis is indicated to prevent oxalosis, even if the glomerular filtration rat …
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators. Cuzick J, et al. Lancet Oncol. 2010 Dec;11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6. Epub 2010 Nov 17. Lancet Oncol. 2010. PMID: 21087898 Clinical Trial.
BACKGROUND: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage …
BACKGROUND: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastroz …
306 results